Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 5/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283644 | 0.98 | DRD2 (0.46) | DRD2DRD3MCHR1AGTR1AGTR2 | |
| SCHEMBL10282580 | 0.96 | MCHR1 (0.47) | DRD2DRD3MCHR1AGTR1AGTR2 | |
| SCHEMBL1283129 | 0.91 | MCHR1 (0.46) | DRD2DRD3MCHR1AGTR1AGTR2 | |
| SCHEMBL1282449 | 0.91 | DRD3 (0.50) | DRD2DRD3TP53BRD4CREBBP | |
| SCHEMBL1614049 | 0.91 | DRD3 (0.46) | DRD2DRD3MCHR1TP53CNR2 | |
| SCHEMBL1615081 | 0.90 | TP53 (0.47) | MCHR1AGTR1AGTR2TP53CNR2 | |
| SCHEMBL1283017 | 0.90 | SMN1; SMN2 (0.47) | DRD2DRD3TP53CNR2BRD4 | |
| SCHEMBL1283407 | 0.89 | DRD3 (0.46) | DRD2DRD3MCHR1TP53CNR2 | |
| SCHEMBL1284146 | 0.88 | DRD2 (0.45) | DRD2DRD3MCHR1TP53CNR2 | |
| SCHEMBL1615303 | 0.87 | MCHR1 (0.52) | MCHR1AGTR1AGTR2TP53BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | DRD2 4691/4885DRD3 4321/4885MCHR1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.